Prosensa Therapeutics B.V. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Prosensa Therapeutics B.V. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Prosensa Therapeutics B.V. - Product Pipeline Review - 2014', provides an overview of the Prosensa Therapeutics B.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Prosensa Therapeutics B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Prosensa Therapeutics B.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Prosensa Therapeutics B.V.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Prosensa Therapeutics B.V.'s pipeline products

Reasons to buy

- Evaluate Prosensa Therapeutics B.V.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Prosensa Therapeutics B.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Prosensa Therapeutics B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Prosensa Therapeutics B.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Prosensa Therapeutics B.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Prosensa Therapeutics B.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Prosensa Therapeutics B.V. Snapshot 5
Prosensa Therapeutics B.V. Overview 5
Key Information 5
Key Facts 5
Prosensa Therapeutics B.V. - Research and Development Overview 6
Key Therapeutic Areas 6
Prosensa Therapeutics B.V. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Prosensa Therapeutics B.V. - Pipeline Products Glance 10
Prosensa Therapeutics B.V. - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Prosensa Therapeutics B.V. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Prosensa Therapeutics B.V. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Prosensa Therapeutics B.V. - Drug Profiles 15
drisapersen 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
PRO-045 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PRO-044 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PRO-053 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PRO-052 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
PRO-055 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PRO-135 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PRO-289 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PROSPECT 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RNAi Oligonucleotide for Bone Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RNAi Oligonucleotide for Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RNAi Oligonucleotide for Immune Disorders 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RNAi Oligonucleotide for Skin Diseases 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Prosensa Therapeutics B.V. - Pipeline Analysis 32
Prosensa Therapeutics B.V. - Pipeline Products by Target 32
Prosensa Therapeutics B.V. - Pipeline Products by Route of Administration 33
Prosensa Therapeutics B.V. - Pipeline Products by Molecule Type 34
Prosensa Therapeutics B.V. - Pipeline Products by Mechanism of Action 35
Prosensa Therapeutics B.V. - Recent Pipeline Updates 36
Prosensa Therapeutics B.V. - Dormant Projects 43
Prosensa Therapeutics B.V. - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Prosensa Therapeutics B.V., Key Information 5
Prosensa Therapeutics B.V., Key Facts 5
Prosensa Therapeutics B.V. - Pipeline by Indication, 2014 7
Prosensa Therapeutics B.V. - Pipeline by Stage of Development, 2014 8
Prosensa Therapeutics B.V. - Monotherapy Products in Pipeline, 2014 9
Prosensa Therapeutics B.V. - Phase III, 2014 10
Prosensa Therapeutics B.V. - Phase II, 2014 11
Prosensa Therapeutics B.V. - Phase I, 2014 12
Prosensa Therapeutics B.V. - Preclinical, 2014 13
Prosensa Therapeutics B.V. - Discovery, 2014 14
Prosensa Therapeutics B.V. - Pipeline by Target, 2014 32
Prosensa Therapeutics B.V. - Pipeline by Route of Administration, 2014 33
Prosensa Therapeutics B.V. - Pipeline by Molecule Type, 2014 34
Prosensa Therapeutics B.V. - Pipeline Products by Mechanism of Action, 2014 35
Prosensa Therapeutics B.V. - Recent Pipeline Updates, 2014 36
Prosensa Therapeutics B.V. - Dormant Developmental Projects,2014 43
Prosensa Therapeutics B.V., Other Locations 44